🧬 BioMed Pulse · 2026-09-25 02:01 UTC

BIOMED PULSE

September 25, 2026 | Daily Briefing on Longevity, Viruses, and New Cures

⚡ TL;DR

The Bundibugyo virus (Ebola) outbreak in the Democratic Republic of the Congo has now reached 61 health zones across six provinces, making it the largest Ebola outbreak ever recorded in DRC history, with no sign of slowing. Alongside a sharp CDC drug-resistance alarm and fresh Listeria deaths, today's edition carries an urgent tone.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO EBOLA OUTBREAK - DRC (CRITICAL, ACTIVE)

• As of September 10, 2026, the Bundibugyo virus disease (BVD) outbreak has expanded to 61 health zones across six DRC provinces: Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, and Tshopo, plus one new zone, Kayna, in North Kivu. ^[1]
• WHO designated this the largest Ebola outbreak ever reported in DRC, characterized by sustained community transmission and continuing geographic spread. ^[2]
• As of July 15, 2026, a cumulative 2,124 confirmed cases and 828 deaths had been reported from DRC; Uganda also recorded cross-border cases. ^[3]
• The outbreak was first identified May 14, 2026, in Mongbwalu Health Zone, Ituri Province, after WHO was alerted May 5 to a high-mortality illness including deaths among health workers. ^[4]
• CDC mobilized an international Ebola response beginning May 17, 2026, and launched enhanced airport screening at Washington-Dulles and Atlanta. ^{[5] [6] [7]}

DRUG-RESISTANT BACTERIA - UNITED STATES

• A CDC report released September 23, 2026, found a dramatic increase in dangerous drug-resistant bacteria nationwide, raising alarm for clinicians and public health systems. ^[8]
• This finding echoes longstanding CDC warnings that antibiotic-resistant pathogens pose the most serious threats to hospitalized patients. ^[9]

LISTERIA OUTBREAK - PREPARED MEALS (ACTIVE)

• CDC expanded its ongoing Listeria monocytogenes outbreak alert on September 26, 2026 to include additional prepared foods, with 3 new illnesses and 1 additional death reported. ^[10]
• CDC continues urging consumers to check refrigerators and freezers for all recalled prepared meal products and discard them immediately.

CONGENITAL SYPHILIS - UNITED STATES

• New CDC data released September 24, 2026, show U.S. cases of newborn syphilis increased for the 12th consecutive year in 2024, underscoring a continuing maternal STI crisis.

SALMONELLA OUTBREAK - METABOLIC MEALS (ACTIVE)

• As of September 5, 2025, 16 people across 10 states were sickened with a Salmonella strain linked to certain Metabolic Meals home delivery food products.

ANIMAL RABIES - UNITED STATES

• CDC issued a statement September 10, 2026, on increases in animal rabies activity and associated human exposures, urging vigilance with wildlife contact.

WEST NILE VIRUS - UNITED STATES

• CDC flagged an early, record West Nile season as of July 1, 2026, warning Americans to use mosquito repellent and avoid bites.

MEASLES - BANGLADESH

• WHO reported a nationwide measles surge on April 23, 2026, with 19,161 suspected cases and 2,897 laboratory-confirmed cases affecting 58 of 64 districts across all eight divisions of Bangladesh.

YELLOW FEVER - GLOBAL

• WHO reported that from January 1 to May 26, 2026, six countries recorded 79 human yellow fever infections, with transmission persisting into 2026 following an elevated 2025 season in the Americas.

NIPAH VIRUS - INDIA

• A laboratory-confirmed Nipah virus (NiV) case was reported June 25, 2026, in Kozhikode district, Kerala, India; the adult male developed neurological symptoms after onset May 30 and was hospitalized June 10.

HANTAVIRUS (ANDES) - M/V HONDIUS CRUISE SHIP

• The Andes hantavirus (ANDV) outbreak linked to the M/V Hondius cruise ship was reported to WHO May 2, 2026; by the fifth WHO Disease Outbreak News update (July 2, 2026), additional confirmed cases had been identified across multiple countries.
• CDC provided multiple response transcripts through June 24, 2026, confirming active international coordination and continued low risk to the general U.S. public.

MALARIA - GLOBAL MILESTONE

• WHO certified Timor-Leste malaria-free on July 23-24, 2025, recognizing a nationwide elimination campaign launched after the country's 2002 independence.

🧬 LONGEVITY & AGING

SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE (SASP)

• A Europe PMC study in Methods in Molecular Biology characterized the senescence-associated secretory phenotype (SASP) - the inflammatory cocktail that aging or stressed cells release - using multiplex assays in both primary skin cells and iPSC-derived skin cells, offering a new toolkit to study how cellular aging drives tissue dysfunction.

RADIATION-INDUCED CELLULAR SENESCENCE

• Research published in Genes and Disease found that ionizing radiation triggers senescence in dermal papilla cells (which govern hair follicle cycling) by suppressing the FOXM1-KIF20A molecular pathway, providing a mechanistic link between radiation exposure, hair loss, and accelerated skin aging.

MOLECULAR HYDROGEN AS A RADIOPROTECTIVE AGENT

• A paper in Medical Gas Research (September 2026) reviewed evidence that molecular hydrogen may act as a guardian against environmental radiation damage, potentially slowing radiation-driven cellular aging via antioxidant mechanisms.

MRNA NANOPARTICLE RESTORES BONE HEALTH WITH AGE

• Research in Bioactive Materials (August 2026) described a dual-targeting mRNA lipid nanoparticle that restores ABCA1-dependent cholesterol homeostasis in aged bone cells, successfully promoting repair of age-related bone defects in preclinical models - merging mRNA delivery technology with bone longevity medicine.

BONE-REPAIR ORGANOID AFTER TOTAL-BODY IRRADIATION

• A Bioactive Materials study demonstrated that BMP-2-driven osteo-organoids retain key bone-supporting (osteogenic) features and can promote bone repair even after total-body irradiation, relevant to cancer survivors and the aging immune-skeletal axis.

QUERCETIN NANOCOMPOSITE FOR OSTEOPOROTIC BONE

• Scientists published in Bioactive Materials (August 2026) a microenvironment-responsive nanocomposite hydrogel combining quercetin-derived carbon dots, ZIF-8 (a metal-organic framework), and M2 macrophage-derived vesicles to regenerate osteoporotic bone defects - targeting both inflammation and bone formation simultaneously.

EXTRACELLULAR VESICLES IN OSTEOARTHRITIS

• A Bioactive Materials review (September 2026) detailed how extracellular vesicles switch from pathogenic to reparative roles in osteoarthritis depending on cellular context, pointing toward vesicle-based therapies for this common aging joint disease.

HIGH-DOSE FLU VACCINE AND FRAILTY

• A prespecified analysis of the randomized DANFLU-2 trial in Lancet Healthy Longevity found that high-dose influenza vaccine was more effective than standard-dose at preventing hospitalization specifically in frail older adults - the very group at highest risk - suggesting frailty scoring should guide vaccine dosing decisions.

HIP FRACTURE SURGERY ANAESTHESIA IN OLDER PATIENTS

• A multicenter randomized trial (Lancet Healthy Longevity) in Germany compared spinal versus general anaesthesia for hip fracture surgery in older patients, directly addressing one of the highest-mortality perioperative events in the elderly population.

DEPRESCRIBING TRIAL DESIGN IN OLDER ADULTS

• Two Lancet Healthy Longevity commentaries argued that deprescribing trials - studies testing reduction of unnecessary medications in older patients - require a rationale-first framework before choosing a study design, to avoid underpowered or misleading results in polypharmacy research.

NARCICLASINE FOR ATHEROSCLEROSIS

• Single-cell sequencing guided researchers to identify narciclasine (a plant alkaloid) as a dual VCAM-1/ICAM-1 inhibitor in Genes and Disease, with potential to reduce the vascular inflammation central to atherosclerosis and age-related cardiovascular disease.

INTERVERTEBRAL DISC REGENERATION

• A Bioactive Materials review (September 2026) surveyed biomaterial strategies for intervertebral disc regeneration including niche reprogramming, precision drug delivery, and structural reconstruction - addressing a major driver of chronic pain and disability in aging populations.

💊 NEW CURES & APPROVALS

EMPAGLIFLOZIN - RIDHISIDHI PLLC (NDA220758)

• Empagliflozin, an SGLT2 inhibitor originally developed for type 2 diabetes and heart failure, received an original tentative approval (ORIG TA) action from FDA for sponsor Ridhisidhi PLLC; this class of drug has demonstrated cardiovascular and kidney-protective effects relevant to aging-related disease.

VERZENIO (ABEMACICLIB) - ELI LILLY AND CO (NDA208716)

• Eli Lilly received a supplemental approval (SUPPL AP) for Verzenio (abemaciclib), a CDK4/6 inhibitor used in hormone receptor-positive, HER2-negative breast cancer, expanding its approved indications.

INLURIYO (IMLUNESTRANT TOSYLATE) - ELI LILLY AND CO (NDA218881)

• Eli Lilly received a supplemental approval for Inluriyo (imlunestrant tosylate), an oral selective estrogen receptor degrader (SERD) for breast cancer, representing a new mechanism targeting resistant ER-positive tumors.

SPRAVATO (ESKETAMINE) - JANSSEN PHARMACEUTICALS (NDA211243)

• Janssen received a supplemental approval for Spravato (esketamine hydrochloride), the intranasal fast-acting antidepressant indicated for treatment-resistant depression and major depressive disorder with acute suicidal ideation.

AQNEURSA (LEVACETYLLEUCINE) - INTRABIO (NDA219132)

• IntraBio received a supplemental approval for AQNEURSA (levacetylleucine), an amino acid derivative approved for Niemann-Pick disease type C, a rare inherited neurological disorder causing progressive neurodegeneration.

SOHONOS (PALOVAROTENE) - IPSEN (NDA215559)

• Ipsen received a supplemental approval for Sohonos (palovarotene), a retinoic acid receptor gamma agonist approved for fibrodysplasia ossificans progressiva (FOP), an ultra-rare and severely disabling disease in which muscle and connective tissue are replaced by bone.

CYCLOSPORINE - AUROBINDO PHARMA LTD (ANDA219652)

• Aurobindo Pharma received an original approval (ORIG AP) for a generic cyclosporine formulation, an immunosuppressant used in organ transplantation and autoimmune diseases.

ICOSAPENT ETHYL - APOTEX (ANDA209437)

• Apotex received a supplemental approval for generic icosapent ethyl, a purified omega-3 fatty acid (EPA) indicated to reduce cardiovascular risk in high-triglyceride patients already on statins.

🧪 CLINICAL TRIALS

AGUEDA TRIAL - RESISTANCE EXERCISE AND BRAIN HEALTH IN AGING (NCT05186090)

• The AGUEDA (Active Gains in Brain Using Exercise During Aging) randomized controlled trial, updated September 24, 2026, is evaluating the effects of a 24-week resistance exercise program on brain health in cognitively normal adults aged 65-80 years.

BPL-1357 - BROAD INFLUENZA VACCINE CHALLENGE STUDY (NCT07215858)

• A ClinicalTrials.gov-listed study updated September 24, 2026, is testing BPL-1357, a candidate broad-spectrum influenza vaccine, against H1N1 challenge in human volunteers, addressing the unmet need for pandemic-capable flu protection.

BASE-EDITED STEM CELL GENE THERAPY - CXCR4-WHIM SYNDROME (NCT07775313)

• A trial registered September 24, 2026, is studying base-edited hematopoietic stem/progenitor cell gene therapy for WHIM syndrome, a rare immune disorder caused by CXCR4 mutations leading to severe recurrent infections - a direct application of next-generation gene editing to immunodeficiency.

HB-1 FOR PTSD (NCT07499440)

• A randomized, placebo-controlled trial registered September 24, 2026, is evaluating the safety and efficacy of HB-1 versus placebo in adults aged 18-65 with Post-Traumatic Stress Disorder, spanning both male and female participants.

BARICITINIB FOR JOB SYNDROME WITH ATOPIC DERMATITIS / LUPUS-LIKE DISEASE (NCT07262983)

• A trial registered September 24, 2026, is evaluating the safety and tolerability of baricitinib, a JAK1/2 inhibitor, in patients with autosomal dominant hyper-IgE syndrome (Job syndrome) who also have lupus-like disease or atopic dermatitis.

N-ACETYL-D-MANNOSAMINE (MANNAC) FOR PODOCYTE KIDNEY DISEASES (NCT06664814)

• An open-label Phase 2 study updated September 24, 2026, is testing N-acetyl-D-mannosamine (ManNAc) in patients with focal segmental glomerulosclerosis, minimal change disease, and membranous nephropathy - kidney conditions in which critical podocyte cells are damaged, leading to proteinuria.

CART THERAPY MONITORING IN PEDIATRIC AND YOUNG ADULT B-ALL (NCT05621291)

• A multicenter study updated September 24, 2026, is evaluating NGS-based testing and B-cell recovery monitoring to guide post-CAR-T therapy management in children and young adults with B-lineage acute lymphoblastic leukemia, targeting the approximately 50% who achieve durable remission after CART alone.

CORE STABILIZATION EXERCISE FOR BALANCE IN OLDER ADULTS WITH LOW BACK PAIN (NCT07839052)

• A randomized trial registered September 24, 2026, is investigating whether a core stabilization exercise program added to standard physiotherapy improves balance in adults over 65 with chronic non-specific low back pain.

📢 PUBLIC HEALTH

CDC AWARDS 176 MILLION DOLLARS TO STRENGTHEN PUBLIC HEALTH INFRASTRUCTURE

• On September 25, 2026, CDC announced over 176 million dollars in funding distributed to 48 public health partners to strengthen the U.S. public health system - a significant investment given the simultaneous Ebola, drug-resistance, and foodborne outbreak pressures.

CDC YOUTH HEALTH DATA - ENCOURAGING PROGRESS

• CDC data released September 21, 2026, showed encouraging progress in several youth health metrics, though specific indicators were not fully detailed in the summary.

KINDERGARTEN VACCINATION RATES - SLIGHT DECLINE

• CDC data released August 17, 2026, show U.S. kindergarten vaccination rates remain high overall but recorded a 0.1 percent decline in coverage, continuing a small downward trend requiring monitoring.

DRUG OVERDOSE DEATHS DOWN 27 PERCENT IN 2024

• CDC's National Vital Statistics System data released May 14, 2025, showed a 27 percent decrease in drug overdose deaths in 2024, building on a nearly 24 percent drop reported the prior year.

COUNTERFEIT ONLINE PRESCRIPTION MEDICATIONS

• CDC flagged a potential public health risk from individuals ordering counterfeit prescription medications through online pharmacies, noting safety and contamination hazards.

This briefing is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personal health decisions.

📎 Sources

1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
3. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
5. CDC Mobilizes International Response Following Ebola Disease O… — CDC Newsroom
6. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
7. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
8. CDC Report Finds Sharp Rise in Dangerous Drug-Resistant Bacteria — CDC Newsroom
9. CDC Telebriefing: New Vital Signs Report What role is antibiot… — CDC Newsroom
10. CDC expands Listeria outbreak to include more prepared meals — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260925-02-v86 · 2026-09-25 02:01 UTC · pulse.uzylab.com